: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .
Co-founder and CEO announced he will step down from his role and the board by the end of 2026.
: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update
: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth :